Precision oncology diagnostics company developing a scalable, blood-based liquid biopsy that profiles the tumor microenvironment from plasma cell-free DNA
Precision oncology diagnostics company developing a scalable, blood-based liquid biopsy that profiles the tumor microenvironment from plasma cell-free DNA. Its AI platform identifies nine spatial ecotypes to support treatment-response prediction, cancer monitoring, and drug development.